Related references
Note: Only part of the references are listed.Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin plus Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)
Thao Huynh et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial
Stephen N. Davis et al.
DIABETES CARE (2019)
Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific
Eugene S. J. Tan et al.
HEART (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Real-world studies no substitute for RCTs in establishing efficacy
Hertzel C. Gerstein et al.
LANCET (2019)
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Scott D. Solomon et al.
CIRCULATION-HEART FAILURE (2018)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction
Walter J. Paulus et al.
JACC-HEART FAILURE (2018)
Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction
Rebecca Napier et al.
JACC-HEART FAILURE (2018)
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Hertzel C. Gerstein et al.
CIRCULATION (2018)
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes A Network Meta-Analysis
Caroline K. Kramer et al.
JACC-HEART FAILURE (2018)
Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus
Zoltan Papp et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction
Pratik B. Sandesara et al.
DIABETES CARE (2018)
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
Soren L. Kristensen et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
Soren L. Kristensen et al.
CIRCULATION (2017)
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
Soren L. Kristensen et al.
CIRCULATION-HEART FAILURE (2016)
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Markolf Hanefeld et al.
DIABETES CARE (2016)
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
Marc A. Pfeffer et al.
CIRCULATION (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk
Elaine Chow et al.
DIABETES (2014)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial
Peter Carson et al.
JOURNAL OF CARDIAC FAILURE (2009)
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure
Michael R. MacDonald et al.
EUROPEAN HEART JOURNAL (2008)
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction.
Barry M. Massie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
Eldrin F. Lewis et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Predictors of mortality and morbidity in patients with chronic heart failure
SJ Pocock et al.
EUROPEAN HEART JOURNAL (2006)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:: the CHARM-Preserved Trial
S Yusuf et al.
LANCET (2003)
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure
N Suskin et al.
EUROPEAN HEART JOURNAL (2000)